ArticleAnnals of thoracic surgery short reports2026
Midterm Echocardiographic Outcomes of Minimally Invasive Mitral Valve Surgery in Patients With Previous Cardiac Surgery.
Article in Annals of thoracic surgery short reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Minimally invasive mitral valve repair (MVr) and mitral valve replacement (MVR) after previous sternotomy are relatively uncommon. This study reports midterm outcomes at a single institution. Methods: All patients with a history of previous cardiac surgery who underwent minimally invasive MVr and MVR with hypothermic fibrillatory arrest at our institution (Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada) between 2006 and 2024 were included. Follow-up echocardiographic reports were reviewed at 1 year, 1 to 3 years, 3 to 5 years, and 5+ years. Primary outcomes included postoperative complications, all-cause mortality, and rates of grade 3 to 4 mitral regurgitation at follow-up. Results: A total of 31 patients met the inclusion criteria (25.8% female patients), and their median age was 64 years. A total of 18 patients underwent MVR, and 13 underwent MVr. The most common previous cardiac operations were aortic valve replacement (AVR), coronary artery bypass graft, and MVR. All redo procedures were completed using hypothermic fibrillatory arrest (mean, 23.3 [2.5] °C; median duration, 143.0 minutes [interquartile range, 110.5-175.0 minutes]) for myocardial protection. The 30-day, 5-year, and 10-year all-cause mean mortality rates were 0.0% (0.0%), 12.9% (6.0%), and 25.8% (7.9%), respectively. Patients with previous AVR with or without ascending aortic replacement represented 50% of total deaths. Overall, 4 (12.9%) patients had recurrent grade 3 to 4 mitral regurgitation: 3 died, and 1 had subsequent double-redo MVR. Conclusions: Our study demonstrates low perioperative mortality rates, thus implying the safety of fibrillatory arrest for myocardial protection in redo minimally invasive MVr and MVR. We also identified that patients with AVR with or without ascending aortic replacement face a higher midterm risk, given the technical difficulty of operating with fibrillatory arrest on the anterolateral portion of the mitral valve when the aortic annulus or root is inflexible.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.